Metabolism and Disposition of a Novel Selective α7 Neuronal Acetylcholine Receptor Agonist ABT-126 in Humans: Characterization of the Major Roles for Flavin-Containing Monooxygenases and UDP-Glucuronosyl Transferase 1A4 and 2B10 in Catalysis

• Published in: Drug metabolism and disposition Vol. 46; no. 4; pp. 429 - 439
• Main Authors: Liu, Hong, Stresser, David M, Michmerhuizen, Melissa J, Li, Xiaofeng, Othman, Ahmed A, Reed, Aimee D, Schrimpf, Michael R, Sydor, Jens, Lee, Anthony J
• Format: Journal Article
• Language: English
• Published: Bethesda American Society for Pharmacology and Experimental Therapeutics, Inc 01-04-2018
• Subjects: Catalysis; Dimethylaniline monooxygenase (N-oxide-forming); Drug dosages; Excretion; Feces; Flavin; Glucuronosyltransferase; Hepatocytes; Kidneys; Liver; Metabolism; Metabolites; Monkeys; Oxidation; Pharmacology; Radioactivity; Uridine; Urine
• ISSN: 0090-9556; 1521-009X
• DOI: 10.1124/dmd.117.077511

Mass balance, metabolism, and excretion of ABT-126, an α7 neuronal acetylcholine receptor agonist, were characterized in healthy male subjects (n = 4) after a single 100-mg (100 μCi) oral dose. The total recovery of the administered radioactivity was 94.0% (±2.09%), with 81.5% (±10.2%) in urine and 12.4% (±9.3%) in feces. Metabolite profiling indicated that ABT-126 had been extensively metabolized, with 6.6% of the dose remaining as unchanged parent drug in urine. Parent drug accounted for 12.2% of the administered radioactivity in feces. The primary metabolic transformations of ABT-126 involved aza-adamantane N-oxidation (M1, 50.3% in urine) and aza-adamantane N-glucuronidation (M11, 19.9% in urine). M1 and M11 were also major circulating metabolites, accounting for 32.6% and 36.6% of the drug-related material in plasma, respectively. These results demonstrated that ABT-126 is eliminated primarily by hepatic metabolism, followed by urinary excretion. Enzymatic studies suggested that M1 formation is mediated primarily by human liver flavin-containing monooxygenase (FMO)3 and, to a lesser extent, by human kidney FMO1; M11 is generated mainly by human uridine 5′-diphospho-glucuronosyltransferase (UGT) 1A4, whereas UGT 2B10 also contributes to ABT-126 glucuronidation. Species-dependent formation of M11 was observed in hepatocytes; M11 was formed in human and monkey hepatocytes, but not in rat and dog hepatocytes, suggesting that monkeys constitute an appropriate model for predicting the fate of compounds undergoing significant N-glucuronidation. M1 and M11 are not expected to have clinically relevant on- or off-target pharmacologic activities. In summary, this study characterized ABT-126 metabolites in the circulation and excreta and the primary elimination pathways of ABT-126 in humans.